Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Semi-annual Business Results
November 8, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 8, 2004
- Business Forecast
November 8, 2004
- Postoperative Adjuvant Therapy Recommended as Grade A Standard for Lung Cancer: JLCS
November 8, 2004
- BUSINESS NEWS IN BRIEF
November 8, 2004
- GL on Clinical Evaluation of Anti-Malignant Tumor Agents Revised
November 8, 2004
- Degussa Japan Opens New Pharmapolymers Technical Center
November 8, 2004
- Length of Clinical Trials Averages 555 Days: JPMA
November 8, 2004
- Price Negotiations Proceeding More Quickly This Year: Kraft
November 8, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 8, 2004
- BULLETIN
November 8, 2004
- Korosho to Build Up Core Hospital Network to Collect ADR Reports
November 8, 2004
- Importance of Alliance Increases for Domestic Companies: OPIR Report
November 8, 2004
- PMDA to Fund Regional Clinical Trial Network Project
November 8, 2004
- Mediceo Group Plans to Strengthen Healthcare Division
November 8, 2004
- Pharmacists Have Responsibility to Be "Drug Pros": Seminar
November 8, 2004
- AnGes MG Expecting 1st Product Launch in 2006
November 8, 2004
- Alan Bootes to Step Down as President of Pfizer Japan
November 8, 2004
- BULLETIN
November 8, 2004
- WORLD NEWS IN BRIEF
November 8, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…